Trial reportProstate cancer and prostatic diseases2013
RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients.
Trial report in Prostate cancer and prostatic diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 5 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Efficacy of anti-osteoporosis treatment for men with osteoporosis: a meta-analysis.Journal of bone and mineral metabolism · 2023Pooled it
- Pooled it
- Does Routine Anti-Osteoporosis Medication Lower the Risk of Fractures in Male Subjects? An Updated Systematic Review With Meta-Analysis of Clinical Trials.Frontiers in pharmacology · 2019Pooled it
- Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults.The Cochrane database of systematic reviews · 2018Pooled it
- Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis.Journal of the American Geriatrics Society · 2017Pooled it
- A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [Molecular imaging and biology · 2017Trial
- Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti-Oestrogen Therapy for Breast Cancer.Cancer medicine · 2025Review
- Article
- Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications.Cancers · 2023Review
- Understanding Molecular Mechanisms and Identifying Key Processes in Chronic Radiation Cystitis.International journal of molecular sciences · 2022Review
- Bone Health in Men with Prostate Cancer: Review Article.Current osteoporosis reports · 2019Review
- The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer.Advances in urology · 2018Review
- Managing bone metastases and reducing skeletal related events in prostate cancer.Nature reviews. Clinical oncology · 2014Review
- Prostate cancer treated with androgen deprivation therapy has consequences for bone.Endocrine · 2014Article
- Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade.SpringerPlus · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 2 countries.
Funding
Abstract
backgroundRTOG 0518 evaluated the potential benefit of zoledronic acid therapy in preventing bone fractures for patients with high grade and/or locally advanced, non-metastatic prostate adenocarcinoma receiving luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy (RT).
methodsEligible patients with T-scores of the hip (<-1.0, but >-2.5 vs >-1.0) and negative bone scans were prospectively randomized to either zoledronic acid, 4 mg, concurrently with the start of RT and then every six months for a total of 6 infusions (Arm 1) or observation (Arm 2). Vitamin D and calcium supplements were given to all patients. Secondary objectives included quality of life (QOL) and bone mineral density (BMD) changes over a period of three years.
resultsOf 109 patients accrued before early closure, 96 were eligible. Median follow-up was 36.3 months for Arm 1 and 34.8 months for Arm 2. Only two patients experienced a bone fracture (one in each arm) resulting in no difference in freedom from any bone fracture (P=0.95), nor in QOL. BMD percent changes from baseline to 36 months were statistically improved with the use of zoledronic acid compared to observation for the lumbar spine (6% vs -5%, P<0.0001), left total hip (1% vs -8%, P=0.0002), and left femoral neck (3% vs -8%, P=0.0007).
conclusionsFor patients with advanced, non-metastatic prostate cancer receiving LHRH agonist and RT, the use of zoledronic acid was associated with statistically improved BMD percent changes. The small number of accrued patients resulted in decreased statistical power to detect any differences in the incidence of bone fractures or QOL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.